logo
  • Home
  • News
Menu

PharmaCyte Biotech Announces Reverse Stock Split

Home / Stock Analysis / PharmaCyte Biotech Announces Reverse Stock Split
Article feature image

PharmaCyte Biotech Announces Reverse Stock Split

09 Jul Stock Analysis

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (OTCQB: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®,…

Click here to view the original article.

Tags:
Business Wire, Global
Facebook Google+ Twitter Pinterest
  Previous
Next  

Related Posts

1585187245570.jpeg
+

Zimplats Holdings Limited’s (ASX:ZIM) 27% Share Price Surge Not Quite Adding Up

10 Oct Stock Analysis
1756254649154.jpeg
+

Colgate-Palmolive (CL): Evaluating Undervaluation After Recent 8% Share Price Decline

10 Oct Stock Analysis

recent post

  • FI-Rob-Biederman.jpg

    Due diligence reshaping AI investing strategy

    Oct 10 2025
  • 1585187245570.jpeg

    Zimplats Holdings Limited’s (ASX:ZIM) 27% Share

    Oct 10 2025
  • news-story.jpg

    SEC’s ‘future-proofing’ push to shape how

    Oct 10 2025
  • 1756254649154.jpeg

    Colgate-Palmolive (CL): Evaluating Undervaluation After Recent

    Oct 10 2025
  • 1760130047_Morgan-Stanley.jpg

    Morgan Stanley to Allow Agents to

    Oct 10 2025

Categories

  • Business
  • Crypto News
  • Investing Strategy
  • People
  • Stock Analysis

©2019.  All Rights Reserved.